ClinicalTrials.gg
RecruitingNCT07204314Updated Oct 29, 2026

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine tablets and Placebo tablets in Major Depressive Disorder, sponsored by Takeda. Recruiting at 30 sites in Japan. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 29, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Planned enrollment
32nd of 54
180 · median 413
Started
2025
the only one that year
Phase 3
31 of 54
1 open now
Registered
54th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 32nd largest by planned enrollment, is the only one that started in 2025, is one of 31 in phase 3, and was the 54th registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country.

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 295 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The main aim of the study is to check how well vortioxetine 10 mg/day or 20 mg/day works and to check for side effects compared to a placebo on depression symptoms in Japanese teenagers aged 12 to 17 years with a diagnosis of Major Depressive Disorder (MDD).

The overall time each participant will be in the study is about 20 weeks. This includes up to 15 days (about 2 weeks) to check who can take part, a 14-week period where everyone receives vortioxetine or a placebo, and after that, a 4-week period to check for any side effects after treatment.

During the study, participants will visit their clinic 13 times.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Drug Therapy
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The Japanese participant is a male or female, aged 12 to 17 years at the time of (patients who turn 18 years during the trial will be allowed to continue in the trial).
  2. The participant is capable of communicating with the site personnel.
  3. The participant is able to understand the informed assent form or the ICF and parent(s)/legal guardian(s) are able to read and understand the ICF. The participant is able and willing to accept video recording at the assessment by the trial site and evaluation by third party evaluators (Central Evaluating Committee).
  4. The participant has provided the written informed assent as much as possible to participation and parent(s)/legal guardian(s) signed the ICF.
  5. The participant and parent(s)/legal guardian(s) are willing and able to attend trial appointments within the specified time windows.
  6. The participant is an outpatient consulting a clinician.
  7. The participant has a primary diagnosis of MDD or persistent depressive disorder and fully meet the criteria for major depressive episodes according to without psychotic features although co-morbid anxiety disorders will be permitted. The diagnoses will be confirmed using the MINI-KID.
  8. The participant has a CDRS-R total score greater than or equal to 45 at the Screening Visit and at the Baseline A Visit (Week 0).
  9. The participant has a CGI-S score greater than or equal to4 at the Screening Visit and at the Baseline A Visit (Week 0).
  10. The participant has a PHQ-A score of greater than or equal to10 at the Baseline A Visit (Week 0).
  11. The participant, if a female and is capable of producing viable ova, agrees to the following, for the period from the signing of ICF until 30 days after the last dose of trial intervention.

    • To use a highly effective or acceptable method
    • To avoid donating ova
  12. The participant, if a female, must have a confirmed negative urine pregnancy test at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  1. The participant has previously been entered and moved to Phase A in this trial.
  2. The participant has participated in a clinical trial less than 30 days before the Screening Visit.
  3. The participant is a member of the trial personnel or of their immediate families or is a subordinate (or immediate family member of a subordinate) to any of the trial personnel.
  4. The participant has been previously treated with vortioxetine.
  5. The participant has the current or previous major depressive episode which was considered by the investigators to have been resistant to 2 or more adequate antidepressants treatments of at least 6-weeks duration each at sufficient doses.
  6. The participant is under forced treatment.
  7. The participant has experienced any environmental change (eg, hospitalization, change of residence) considered by the investigator to have the potential impact on the participant's disease situation or plans such environmental changes during the trial.
  8. The participant is pregnant or breast-feeding.
  9. The participant receives on-going psychotherapy (except for a supportive psychotherapy) that is started less than 3 months before the Baseline A Visit (Week 0) and/or that is planned to be intensified during the trial.
  10. The participant has a history of severe drug allergy or or known hypersensitivity to any of the IMPs or their .
  11. The participant has hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltose insufficiency.
  12. The participant has any current psychiatric disorder, including posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD) as assessed using the MINI-KID. If the MINI-KID screening assessment suggests the presence of any current psychiatric disorders other than permitted co-morbid anxiety disorders, the participant may be enrolled only if an additional evaluation confirms that the participant does not meet criteria for that disorder at Screening, as determined by the investigator.
  13. The participant has a medical history of substance use disorder (excluding nicotine, and caffeine) or alcohol use disorder (DSM-5-TR criteria) less than 6 months before the Screening Visit.
  14. The participant has reported current use of or has tested positive for drugs of abuse (opiates, methadone, cocaine, amphetamines [including ecstasy], barbiturates, benzodiazepines, and cannabinoids, etc).
  15. The participant suffers from medical, organic or drug cause mental disorders (DSM-5-TR criteria).
  16. The participant has a known intellectual disability; or clinical evidence or known social or school history indicative of intellectual disability.
  17. The participant has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with trial treatment or impair treatment compliance.
  18. The participant has a history of moderate or severe head trauma; or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect central nervous system functioning.
  19. The participant has a known first degree relative with a history of bipolar disorder.
  20. The participant is unable to swallow tablets.
  21. The participant has a history of cancer that has not been in remission for more than 5 years before the first dose of trial intervention.
  22. The participant has or has had 1 or more of the following conditions that is/are considered in the context of the trial: neurological disorder, other psychiatric disorder, cardiovascular disease, seizure disorder or encephalopathy, congestive heart failure, cardiac hypertrophy, arrhythmia, bradycardia (pulse less than 50 bpm), respiratory disease, hepatic impairment or renal insufficiency, metabolic disorder, endocrinological disorder, gastrointestinal disorder, hematological disorder, infectious disorder, any clinically significant immunological condition, dermatological disorder, venereal disease, congenital or juvenile glaucoma or is at risk of acute narrow-angle glaucoma
  23. The participant takes or has taken disallowed recent or concomitant medication, or it is anticipated that the participant will require treatment with at least one of the disallowed concomitant medications/procedures or treatment during the trial.
  24. The participant has clinically significant abnormal vital signs at the Screening Visit.
  25. The participant has 1 or more clinical laboratory test values outside the reference range, based on the blood and urine samples taken at the Screening Visit, which are of potential risk to the participant's safety; or the participant has, at the Screening Visit:

    • a serum creatinine value more than 1.5 times the upper limit of the reference range
    • a serum total value more than 1.5 times the upper limit of the reference range
    • a serum or AST value more than 2 times the upper limit of the reference range
  26. The participant has an abnormal TSH level. Participant with thyroid disease may be enrolled in the trial provided they are stable and euthyroid at the discretion of the investigator.
  27. The participant has, at the Screening Visit:

    • an abnormal that is, in the investigator's opinion, clinically significant
    • a interval more than 450 ms (based on the Fridericia correction where QTcF = QT/RR0.33)
  28. The participant has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the trial.
  29. The participant is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.
  30. The participant has attempted suicide within the last 12 months or is at significant risk of suicide (either in the opinion of the investigator or defined as a 'yes' to suicidal ideation questions 4 or 5 or answering 'yes' to suicidal behavior questions on the C-SSRS within the last 12 months).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Vortioxetine

    Participants will receive the study drug, orally, once, daily (QD) for 14 weeks. The vortioxetine dose will be started at 10 mg per day, and can be increased to 20 mg per day.

    Drug: Vortioxetine tablets

  • Placebo comparator
    Placebo

    Participants will receive the study drug, orally, once, daily (QD) for 14 weeks.

    Drug: Placebo tablets

Interventions

  • Vortioxetine tablets

    Also known as: Trintellix

  • DrugPlacebo tablets

    Placebo tablets

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Children Depression Rating Scale Revised version (CDRS-R) Total Score

    The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R is rated by a clinician following interviews with the child and parents/legal guardians and consists of 17 items out of which 3 items rate nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items are rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) are scored on a 5-point scale from 1 to 5. The total score ranges from 17 (normal) to 113 (severe depression). Higher scores indicate greater severity of depression.

    Time frame: Baseline, Week 14

Secondary outcomes

  1. Change from Baseline in the CDRS-R Total Score at Each Time Point

    The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R is rated by a clinician following interviews with the child and parents/legal guardians and consists of 17 items out of which 3 items rate nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items are rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) are scored on a 5-point scale from 1 to 5. The total score ranges from 17 (normal) to 113 (severe depression). Higher scores indicate greater severity of depression.

    Time frame: Baseline, Week 2, 4, 6, 8, and 10

  2. CDRS-R Response at Each Time Point

    CDRS-R response is defined as at least 50 percent reduction in the CDRS-R total score from Baseline, calculated as the change from baseline divided by the result of subtracting 17 from the Baseline score. CDRS-R response at each time point will be reported.

    Time frame: Week 2, 4, 6, 8, 10, and 14

  3. Remission at Each Time Point

    Remission is defined as less than or equal to 28 in the CDRS-R total score. Remission at each time point will be reported.

    Time frame: Week 2, 4, 6, 8, 10, and 14

  4. Change from Baseline in the Patient Health Questionnaire-9 for Adolescents (PHQ-A) at Each Time Point

    The PHQ-A is a participant-rated scale designed to screen for depressive symptoms in adolescents. The 9 depression items are rated on a 4-point scale (0=Not at all; 1=Several days; 2=More than half the days; and 3=Nearly every day). The total score can range from 0 to 27, with higher scores indicating greater severity of depression.

    Time frame: Baseline, Week 4, 6 and 14

  5. Change from Baseline in the Digit Symbol Substitution Test (DSST) at Each Time Point

    The DSST is a paper-and-pencil cognitive test. After viewing a predetermined table of pairs of numbers and symbols, participants replace each symbol with its corresponding number, one by one. The number of correct symbols within the allowed time, usually 90 seconds, constitutes the score. The DSST score ranges from 0 to 133, with lower scores indicating lower cognitive function.

    Time frame: Baseline, Week 4 and 14

  6. Change from Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Each Time Point

    The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill participants).

    Time frame: Baseline, Week 2, 4, 6, 8, 10, and 14

  7. Score in the Clinical Global Impression - Global Improvement (CGI-I) at Each Time Point

    The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Week 4, 6, 8, 10, and 14

  8. Remission in the CGI-S Score at Each Time Point

    Remission in the CGI-S score is defined as a CGI-S score of 1 or 2. Remission in the CGI-S score at each time point will be reported.

    Time frame: Week 2, 4, 6, 8, 10, and 14

  9. Response in the CGI-I Score at Each Time Point

    Response in the CGI-I Score is defined as defined as a CGI-I score of 1 or 2. Response in the CGI-I score at each time point will be reported.

    Time frame: Week 4, 6, 8, 10, and 14

  10. Change from Baseline in the Sheehan Disability Scale - Adolescent Version (SDS-A) at Each Time Point

    The SDS-A assesses functional impairment in 3 major life domains: school/work, social life/leisure activities, and family life/home responsibilities. The 3 life domains are rated on a 11-point scale from 0 (Not at all) to 10 (Extremely). The total score ranges from 0 to 30, with higher scores indicating greater pathology.

    Time frame: Baseline, Week 4 and 14

  11. Plasma Concentrations of Vortioxetine

    Time frame: Week 6, 10, and 14

07

Study locations

30 of 30 sites recruiting
  • Nagoya City University Hospital
    Nagoya, Aichi-ken, Japan
    Recruiting
  • Hirosaki University Hospital
    Hirosaki, Aomori, Japan
    Recruiting
  • Kaku Mental Clinic
    Chūōku, Fukuoka, Japan
    Recruiting
  • Jisenkai Nanko Psychiatric Institute
    Shirakawa, Fukushima, Japan
    Recruiting
  • Hokkaido University Hospital
    Sapporo, Hokkaido, Japan
    Recruiting
  • NHO Shikoku Medical Center for Children and Adults
    Zentsujichó, Kagawa-ken, Japan
    Recruiting
  • St. Marianna University School of Medicine Hospital
    Kawasaki, Kanagawa, Japan
    Recruiting
  • Kanagawa Children's Medical Center
    Yokohama, Kanagawa, Japan
    Recruiting
  • Yokohama City University Hospital
    Yokohama, Kanagawa, Japan
    Recruiting
  • Kochi Medical School Hospital
    Nankoku, Kochi, Japan
    Recruiting
  • Tohoku University Hospital
    Sendai, Miyagi, Japan
    Recruiting
  • Miyakonojo Shinsei Hospital
    Miyakonojō, Miyazaki, Japan
    Recruiting
  • Nara Medical University Hospital
    Kashihara, Nara, Japan
    Recruiting
  • Bandai Mental Clinic
    Chuo-ku, Niigata, Japan
    Recruiting
  • University of the Ryukyus Hospital
    Ginowan, Okinawa, Japan
    Recruiting
  • Imurokokorono-clinic
    Urasoe, Okinawa, Japan
    Recruiting
  • Kindai University Hospital
    Ōsaka-sayama, Osaka, Japan
    Recruiting
  • Dokkyo Medical University Saitama Medical Center
    Koshigaya, Saitama, Japan
    Recruiting
  • Harai Clinic
    Chuo-ku, Tokyo, Japan
    Recruiting
  • Tokyo Metropolitan Children's Medical Center
    Fuchū, Tokyo, Japan
    Recruiting
  • National Center of Neurology and Psychiatry
    Kodaira, Tokyo, Japan
    Recruiting
  • Aiiku Clinic
    Minato-ku, Tokyo, Japan
    Recruiting
  • Pauroom
    Minato-ku, Tokyo, Japan
    Recruiting
  • Kai Kokoro Clinic
    Suginome, Tokyo, Japan
    Recruiting
  • Shin-Otsuka Clinic
    Toshima-ku, Tokyo, Japan
    Recruiting
  • Cerisier Heart Clinic
    Kagoshima, Japan
    Recruiting
  • Yuge Neuropsychiatric Hospital
    Kumamoto, Japan
    Recruiting
  • Chikama Clinic
    Miyazaki, Japan
    Recruiting
  • Osaka Metropolitan University Hospital
    Osaka, Japan
    Recruiting
  • Toyama University Hospital
    Toyama, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2029, 47 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 47 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 2, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2029
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedThe participant has any current psychiatric disorder (DSM-5-TR criteria), including posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD) established as the primary diagnosis, as assessed using the MINI-KID. If the MINI-KID screening assessment suggests the presence of any current psychiatric disorders other than permitted co-morbid anxiety disorders, the participant may be enrolled only if an additional evaluation confirms that the participant does not meet DSM-5-TR criteria for that disorder at Screening, as determined by the investigator.
Oct 29, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time framePlasma Concentrations of VortioxetineBaseline, Week 6, 10, and 14 → Week 6, 10, and 14
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedThe participant has any current psychiatric disorder (DSM-5-TR criteria), including posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD) established as the primary diagnosis, as assessed using the MINI-KID. If the MINI-KID screening assessment suggests the presence of any current psychiatric disorders other than permitted co-morbid anxiety disorders, the participant may be enrolled only if an additional evaluation confirms that the participant does not meet DSM-5-TR criteria for that disorder at Screening, as determined by the investigator.
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time framePlasma Concentrations of VortioxetineBaseline, Week 6, 10, and 14 → Week 6, 10, and 14
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07204314
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Oct 1, 2025
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Oct 29, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion